Common types of nanoformulations include liposomes, polymeric nanoparticles, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nano-emulsions, micelles, dendrimers, nanocrystals, and nano-complexes [32]
Third, the approval of orforglipron signals that non-peptide small molecules can replicate peptide receptor pharmacology, potentially disrupting the peptide therapeutics market for some targets
It was approved in 2019 for diabetes management
Watch for these inconsistencies: Old Dates: COAs that are months or years old dont reflect the current batch
Weight loss outcomes similarly show a gradient of effectiveness
25 Given concerns that skeletal muscle loss may predispose patients to long-term metabolic complications, including sarcopenia, it is recommended that individuals undergoing treatment with GLP-1 RAs receive adequate protein intake and appropriate micronutrient supplementation to preserve muscle mass and function, thereby maximizing the clinical benefits of therapy
